CHPF2

CHPF2 (ChSy-3/CSGlcA-T/KIAA1402) is a type II transmembrane glycosyltransferase that drives chondroitin sulfate (CS) chain biosynthesis as an obligate partner of the CHSY family (PMID:12145278, PMID:41298522). As a soluble catalytic domain it transfers glucuronic acid to GalNAc termini of chondroitin acceptors, forming the GlcAβ1-3GalNAc linkage, with no detectable GalNAc-transferase activity or activity toward dermatan sulfate, heparan sulfate, or hyaluronan (PMID:12145278). CS polymerization requires CHPF2 to physically associate with a CHSY subunit (CHSY1, CHSY3, or ChPF): cryo-EM and catalytic-mutant analysis establish that within the heterodimer CHPF2 does not itself contribute glycosyltransferase activity but stabilizes the enzymatically active CHSY subunit, with polymerization proceeding by a non-processive, distributive mechanism dictated by the spatial arrangement of catalytic sites (PMID:41298522, PMID:42204168). CHPF2 contains an N-terminal GT31-like domain and a C-terminal GT7-like domain separated by a cystatin-like bridging domain, and the heterodimer is necessary to produce a soluble, functional CS synthase (PMID:42204168). Functionally, CHPF2 governs CS chain length: its loss reduces the molecular weight of cell-surface CS and the accessibility of length-dependent ligands such as the malarial rVAR2 protein (PMID:34762909), and astrocyte CHPF2 produces secreted CS-GAGs that restrain dendritic arborization of developing hippocampal neurons (PMID:40192069). Beyond CS synthesis, CHPF2 carries out non-canonical signaling functions: its product chondroitin-4-sulfate enhances CK2-PTEN binding to sustain AKT activation selectively in BRAF V600E melanoma (PMID:29547721), and upon TNF stimulation MEK-mediated phosphorylation at T588 enables CHPF2 to scaffold TAK1 and IKKα, amplifying NF-κB signaling to upregulate EGR1 and promote colorectal cancer proliferation and metastasis independently of its glycosyltransferase activity (PMID:38253217).

1. 2002 High

   Established the core biochemical identity of CHPF2 by defining it as a glucuronyltransferase acting on chondroitin acceptors, distinguishing it from GalNAc-transferases and other GAG-modifying enzymes.

   Evidence Expression of the soluble catalytic domain in COS-7 cells with in vitro glycosyltransferase assays against defined acceptors, validated by β-glucuronidase digestion and K4 polymerase extension

   PMID:12145278

   Open questions at the time

   • Did not address whether the enzyme acts alone in cells
   • No structural basis for substrate selectivity
   • Did not place activity within a polymerizing complex
2. 2008 High

   Resolved why the isolated enzyme cannot polymerize CS by showing CHPF2 only elongates chains when partnered with a ChSy family member, while its own catalytic activity is still required for elongation.

   Evidence Co-expression with ChSy-1/ChSy-2/ChPF, in vitro polymerization with linkage-region tetrasaccharide acceptor, glycosyltransferase-dead mutagenesis, plus RNAi and overexpression CS quantification

   PMID:18316376

   Open questions at the time

   • Architecture of the active complex unresolved
   • Relative catalytic contribution of each subunit not quantified
   • Mechanism of polymerization (processive vs distributive) unknown
3. 2018 Medium

   Identified a product-mediated signaling role in which the CS product chondroitin-4-sulfate sustains oncogenic AKT signaling in a genotype-specific manner.

   Evidence CK2-PTEN co-immunoprecipitation, PTEN phosphorylation assays, CHSA supplementation/depletion, and genetic rescue in BRAF V600E vs NRAS/PI3KCA backgrounds with xenografts

   PMID:29547721

   Open questions at the time

   • No in vitro reconstitution of direct CK2-PTEN-CHSA interaction
   • Single lab
   • Genotype-restricted dependence not generalized
4. 2021 High

   Connected CHPF2 enzymatic output to a functional surface phenotype, showing it controls CS chain length and thereby length-dependent ligand accessibility.

   Evidence CRISPR/Cas9 knockout in tumor cells with CS molecular weight measurement and rVAR2 binding assay in a glycocalyx model

   PMID:34762909

   Open questions at the time

   • Did not resolve subunit contributions to chain length
   • Generality across cell types untested
   • No structural explanation for length control
5. 2024 High

   Revealed a glycosyltransferase-independent scaffolding function in which phosphorylated CHPF2 bridges TAK1 and IKKα to amplify NF-κB signaling.

   Evidence T588A phospho-deficient mutagenesis, Co-IP of CHPF2 with TAK1/IKKα, kinase assays linking MEK to T588, NF-κB reporter assays, and in vitro/in vivo CRC growth models

   PMID:38253217

   Open questions at the time

   • Structural basis of the CHPF2-TAK1-IKKα scaffold not defined
   • Single lab
   • Interplay between scaffolding and enzymatic pools of CHPF2 unclear
6. 2025 High

   Determined the molecular mechanism of the CS synthase, establishing that CHPF2 is a non-catalytic stabilizer of the active CHSY subunit and that polymerization is non-processive/distributive.

   Evidence Cryo-EM of CHSY3-CHPF complex, in vitro glycosylation with fluorescent substrates, catalytic mutagenesis of purified complexes, and in cellulo complementation

   PMID:41298522

   Open questions at the time

   • Functional distinction between CHSY1- and CHSY3-containing complexes not resolved
   • Regulation of complex assembly in vivo unknown
7. 2025 Medium

   Extended CHPF2 function to a developmental context, linking astrocyte CHPF2-dependent CS-GAG secretion to inhibition of neuronal dendritic arborization.

   Evidence TRAP-seq, siRNA knockdown of Chpf2 in astrocytes, LC/MS CS-GAG quantification, and astrocyte-conditioned medium transfer to hippocampal neurons with neurite quantification

   PMID:40192069

   Open questions at the time

   • CS structural features mediating neurite inhibition not defined
   • In vivo developmental relevance untested
   • Single lab
8. 2026 High

   Defined CHPF2 domain architecture and confirmed across an independent lab that its GT domains do not contribute to polymer synthesis, requiring heterodimerization for a soluble functional synthase.

   Evidence Sequence alignment/structural modeling, cryo-EM of CHSY3-CHPF1 complex, catalytic domain mutagenesis, and co-expression solubility/enzymatic assays

   PMID:42204168

   Open questions at the time

   • Precise contribution of cystatin-like linker to synthesis not quantified
   • How CHPF2 confers solubility/stability mechanistically unresolved

• It remains unknown how CHPF2's distinct roles — non-catalytic CS-synthase stabilizer versus phosphorylation-dependent NF-κB scaffold and CS-product-mediated AKT signaling — are partitioned and regulated within a single cell.
• No study integrates the enzymatic and signaling pools of CHPF2
• Regulation switching between functions undefined
• Structural basis of the signaling scaffold absent